OptiTROP-Lung06

This preplanned interim analysis shows a large progression-free survival benefit by blinded central review, together with fewer grade 3 or higher haematological adverse events than chemotherapy plus pembrolizumab. With a median follow-up of 9.7 months the overall survival data are immature and no P value is given for them, so the benefit rests on a surrogate endpoint for now. Response rates were similar between the arms, which suggests the PFS gain comes mainly from more durable responses. The abstract does not say whether treatment was open label, does not name the chemotherapy regimen, and gives no subgroup, quality-of-life or discontinuation data; the trial was funded by Sichuan Kelun-Biotech.